|Bid||33.21 x 800|
|Ask||33.26 x 800|
|Day's Range||32.00 - 34.29|
|52 Week Range||17.20 - 34.29|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||14.06|
|Earnings Date||Aug 16, 2021 - Aug 20, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:30 p.m. ET. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay will be available for 60 days on the Company's website following the conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders. For more information, please visit www.supernus.com. CONTACTS: Jack A. Khattar, President and CEOJim Kelly, Executive Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591 Or Investor Contact:Peter VozzoWestwicke/ICROffice: (443) 213-0505Mobile: (443) 377-4767Email: firstname.lastname@example.org